Despite the recent major advancement in therapy for multiple myeloma, it remains 
an incurable disease. There remains an unmet need for novel therapies that 
target different mechanisms of action. Immunotherapy with monoclonal antibodies 
is a promising area of development and will expand our therapeutic armamentarium 
in the fight against myeloma. Daratumumab is a novel, high-affinity, therapeutic 
human monoclonal antibody against unique CD38 epitope with broad-spectrum 
killing activity. It has a favorable safety profile as monotherapy in patients 
with relapsed/refractory myeloma and also demonstrates significant single-agent 
activity. Abundant preclinical data supports its use in combination therapy and 
clinical studies on various exciting combinations are underway. This review 
focuses on the CD38 antigen and its targeting with daratumumab and provides an 
update on the results of recent clinical studies involving daratumumab.